INTRODUCTION
Breast cancer is one of the most common malignancy among women, but it is not common in men. MBC is a rare disease and accounts for ∼1% of all cancers in men. 1 However, in the past 25 years, an increased incidence is seen. 2 The incidence of MBC is higher in North America and Europe as compared with other Asian countries. 3 The highest overall rates adjusted for age occur in Israel (1.08 per 100,000 person-years), while the rates are the lowest in Southeast Asia, particularly in Thailand (0.14 per 100000 personyears) Because of the rarity of the disease most of the information is available in the form of case series and case reports. 4 Pre-disposing factors for MBC include family history (in the first degree relative), hormones (high estrogen and prolactin levels), radiation exposure, diseases associated with hyperestrogenemia like cirrhosis of the liver and genetic syndromes, such as Klinefelter disease. 5 About 90% of MBC are estrogen receptor (ER) positive and triple negative tumors are rare. Objectives were to study the clinic-pathological characteristics and outcome of MBC patients at the institute was defined as the time period between diagnosis and death from any cause. Disease free survival (DFS) (only for non-metastatic patients) was defined as the time period from diagnosis to the occurrence of relapse.
RESULTS
Total 20 patients were included in the study. No risk factor identified in any patient. Clinicopathological details are depicted in ( Table 1 ). The median age at diagnosis was 57.5 years (range:) Most common location was central quadrant (12/20) , followed by upper outer quadrant (4/20). Most common presentation was lump (16/20) followed by ulcer (4/20) . The median clinical tumor size was 3.5 cm. Most common stage at presentation was stage 3. Stage shown in Table 1 is pathological except for metastatic tumors for which clinical staging was used. Three patients presented with metastatic disease, (15%) ER, PR and HER2/neu positivity rate was 75%, 50% and 35%, respectively. (Figure 1 ). The DFS was not significantly associated with nodal status, hormonal status and stage of the disease. 
DISCUSSION
Approximately 15%-20% of men with breast cancer report a family history of breast or ovarian cancer. It is estimated that approximately 10% of men with breast cancer have a genetic predisposition, and BRCA2 is the most clearly associated gene mutation. [6] [7] [8] In this study no family history was found. Men with a family history of breast cancer in a female relative have 2.5 times the odds of developing breast cancer. 9 Prior radiation as in case of mantle field for Hodgkin lymphoma also increases the risk of a subsequent breast cancer. 10 Alcohol use, liver disease, obesity, electromagnetic field radiation, and diet have all been proposed as risk factors, but findings have been inconsistent across studies. [11] [12] [13] [14] Review of surveillance, epidemiology and end result (SEER) data indicate a rise in the incidence of MBC, from 1.0/100,000 men in the late 1970s to 1.2/100,000 men from 2000 to 2004. 15 This study showed that the median age of MBC diagnosis is 57.5 years (range: 28-80 years), which is 10 years earlier than other studies. 16, 17 Analysis from the SEER cancer registry show that 93.7% of MBCs are ductal or unclassified carcinomas and only 1.5% are lobular. 18 Invasive ductal carcinoma was the most common histological subtype in this study and rest were apocrine and mucinous carcinoma. Approximately, 90% of MBCs express the ER, 81% express the PR and 2-15% over express HER2/neu. [19] [20] [21] In this study, ER positivity rate of 78%, PR positivity rate of 75% and HER2 positivity rate of 28%.
Staging of MBC is the same as that in women using the TNM system. 22 The most important prognostic indicators are stage at diagnosis and lymph node status. MBC most commonly develops in the central retro-areolar/nipple area which has the greatest lymphatic drainage in the breast. In this study also the most common location was central quadrant. Since 1970, radical mastectomies have been replaced with the MRM Thus, the MRM is the standard treatment for MBC at present. [23] [24] [25] [26] A total of 17 patients underwent surgery at the center; one of them had lumpectomy at private sector and completion MRM was done at the centre. MRM was the most common procedure at the institute. BCS was done in two patients (11.8%). In this study, hormone receptor status and stage of tumor were the main prognostic factors.
On reviewing the literature, it was found that most of the articles on MBC are review articles, case series and case reports. It is because of the rarity of the disease. The main limitation of this study was the less number of patients as with other studies.
CONCLUSION
In this study, the patients had a longer time to presentation and advanced disease at presentation. Stage and hormone receptor status were main prognostic factors in this study. Multicentric trials are necessary to understand the predictive and prognostic markers and to improve the outcome.
